1. Safety and effectiveness of isavuconazole in real-life non-neutropenic patients.
- Author
-
Monzó-Gallo, Patricia, Lopera, Carlos, Badía-Tejero, Ana M, Machado, Marina, García-Rodríguez, Julio, Vidal-Cortés, Pablo, Merino, Esperanza, Calderón, Jorge, Fortún, Jesús, Palacios-Baena, Zaira R., Pemán, Javier, Sanchis, Joan Roig, Aguilar-Guisado, Manuela, Gudiol, Carlota, Ramos, Juan C, Sánchez-Romero, Isabel, Martin-Davila, Pilar, López-Cortés, Luis E., Salavert, Miguel, and Ruiz-Camps, Isabel
- Subjects
- *
MYCOSES , *DRUG efficacy , *PATIENTS' attitudes , *MUCORMYCOSIS , *CRYPTOCOCCOSIS - Abstract
• Data regarding the use of isavuconazole in non-neutropenic IFI patients is scarce. • Our study positions isavuconazole as a safe treatment for these patients. • Isavuconazole could be used in patients with QT elongation. • Mortality and clinical response are comparable to other antifungals. • Isavuconazole could replace other triazoles as reference treatment. Information is scarce on clinical experiences with non-neutropenic patients with invasive fungal infection (IFI) receiving isavuconazole. We aimed to report the safety and effectiveness of this drug as a first-line treatment or rescue in real life. A retrospective, observational multicentric study of non-neutropenic patients who received isavuconazole as an IFI treatment at 12 different university hospitals (January 2018-2022). All patients met criteria for proven, probable or possible IFI according to EORTC-MSG. A total of 238 IFIs were treated with isavuconazole during the study period. Combination therapy was administered in 27.7% of cases. The primary IFI was aspergillosis (217, 91.2%). Other IFIs treated with isavuconazole were candidemia (n = 10), mucormycosis (n = 8), histoplasmosis (n = 2), cryptococcosis (n = 2), and others (n = 4). Median time of isavuconazole treatment was 29 days. Only 5.9% (n = 14) of cases developed toxicity, mainly hepatic-related (10 patients, 4.2%). Nine patients (3.8%) had treatment withdrawn. Successful clinical response at 12 weeks was documented in 50.5% of patients. Isavuconazole is an adequate treatment for non-neutropenic patients with IFIs. Toxicity rates were low and its effectiveness was comparable to other antifungal therapies previously reported. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF